Best Building Product Companies To Watch For 2015

Best Building Product Companies To Watch For 2015: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By John Udovich]

  Since the start of 2014, small cap pharmaceutical stocks Achillion Pharmaceuticals, Inc (NASDAQ: ACHN), Pernix Therapeutics Holdings Inc (NASDAQ: PTX) and Amicus Therapeutics, Inc (NASDAQ: FOLD) are up 286.3%, 262.3% and 248.1%, respectively, making them some of the best performing pharmaceutical stocks for the year. However, a one year share performance, especially for anything in the volatile biotech or pharmaceutical sector, could be just a one time fluke. With that in mind, here is what you need to know or be warned about all three small cap pharmaceutical stocks:

• [By John Udovich]

  Small cap hepatitis stock Achillion Pharmaceuticals, Inc (! NASDAQ: ACHN) saw shares jump on Monday only to then have a minor implosion on Tuesday – meaning its worth taking a look at that hiccup and the history of hiccups or successes from other small cap hepatitis stocks like Idenix Pharmaceuticals Inc (NASDAQ: IDIX), Arrowhead Research Corp (NASDAQ: ARWR) and Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY). It should be mentioned that Hepatitis A, B and C are viral infections that together affect an estimated 5% to 6% of Americans and while globally, 2 billion people (1 out of 3 people) have been infected with hepatitis B with  400 million people chronically infected plus 130–150 million people have chronic hepatitis C - meaning there is plenty of room for large and small cap players alike in the space.

• [By Sean Williams]

  With a gain year-to-date of 328% -- that's three hundred and twenty eight percent -- clinical-stage HCV-focused Achillion Pharmaceuticals (NASDAQ: ACHN  ) absolutely crushed Gilead in total return this year. Amazingly, it did so without having a single product on pharmacy shelves.

• [By Ben Levisohn]

  Having a hard time keeping track of all the competitors for Gilead Sciences’ (GILD) Sovaldi? You’re not the only one, so RBC Capital Market’s Michael Yee and team provide a handy table (click for a larger one) listing the companies with drugs in the works, including AbbVie (ABBV),  Bristol-Myers Squibb (BMY), Achillion Pharmaceuticals (ACHN) and Merck (MRK):

source from Top Stocks For 2015:http://www.topstocksblog.com/best-building-product-companies-to-watch-for-2015.html